Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. develops precision therapeutics for serious diseases by targeting the chromatin regulatory system and correcting abnormal gene expression. The company’s news centers on oncology programs derived from its Gene Traffic Control® platform, including FHD-909, a selective SMARCA2 inhibitor for SMARCA4-mutant cancers, and selective CBP, EP300 and ARID1B degrader programs across ER+ breast cancer, multiple myeloma and other hematologic malignancies.
Recurring updates also cover the company’s collaboration with Lilly, preclinical data presentations, financial results, registered direct financing activity, executive appointments and investor-conference participation.
Foghorn Therapeutics (Nasdaq:FHTX), a clinical-stage biotechnology company focused on oncology, will participate in three investor conferences in May 2026.
Management will attend the H.C. Wainwright Bioconnect Investor Conference, 2026 Stifel Virtual Targeted Oncology Forum, and TD Cowen Oncology Innovation Summit, including presentations and one-on-one investor meetings.
Foghorn Therapeutics (Nasdaq: FHTX) provided a Q1 2026 update highlighting clinical progress, preclinical data, collaboration details, and cash runway.
Key points: FHD-909 Phase 1 dose-escalation is on track; preclinical combo with anti-PD-1 showed complete, durable regressions and immune memory; IND-enabling work for CBP and EP300 degraders planned for 2026 with INDs targeted in 2027; cash of approximately $183.6M, runway into first half of 2028.
Foghorn (Nasdaq: FHTX) presented new preclinical data at the 2026 AACR Annual Meeting showing multiple program advances. FHD-909 plus anti-PD-1 produced complete, durable regressions and rechallenge tumor rejection in syngeneic models. Selective CBP degrader FHT-171 showed strong activity in ER+ PDX with favorable tolerability. Selective EP300 degraders outperformed a clinical benchmark in multiple myeloma models. Robust cereblon-based ARID1B degradation was achieved with potential oral bioavailability. Data were shared in oral and poster presentations.
Foghorn Therapeutics (Nasdaq: FHTX) will present new preclinical data at the 2026 AACR Annual Meeting April 17–22, 2026 in San Diego. Data include a selective SMARCA2 inhibitor FHD-909 (combination potential with anti-PD-1 in SMARCA4-mutant lung cancer) and multiple degrader programs: CBP (FHT-171), EP300, and ARID1B.
Oral and poster sessions list presenters, session times, and poster numbers; materials will be accessible in the company’s Science section online.
Foghorn Therapeutics (Nasdaq: FHTX) provided a 2025 financial update and 2026 strategic outlook on March 11, 2026, reporting key pipeline progress and a strengthened balance sheet.
Highlights: FHD-909 Phase 1 dose escalation is advancing; Selective CBP and EP300 degrader programs are tracking to IND-enabling studies in 2026. Collaboration revenue was $30.9M in 2025. Cash, cash equivalents, and marketable securities were $158.9M at year-end 2025, and a $50M registered direct financing in January 2026 extends runway into the first half of 2028.
Foghorn Therapeutics (Nasdaq: FHTX) announced management will participate in two investor conferences: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. EDT and The Citizens Life Sciences Conference on March 11, 2026 at 11:20 a.m. EDT.
Adrian Gottschalk, President and CEO, will present at both events and take one-on-one meetings. A webcast of the TD Cowen presentation will be available in the company investors section for 90 days.
Foghorn Therapeutics (Nasdaq: FHTX) appointed Ryan Maynard as Chief Financial Officer effective February 23, 2026. Mr. Maynard brings over 25 years of biopharma financial leadership, has raised over $1 billion, and led financings and commercial launch planning for approved therapies.
The company noted Maynard’s prior roles at Cara Therapeutics, Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics, his recent transactional work including a $37.5M non-dilutive royalty arrangement, and his board seat at Iovance.
Foghorn Therapeutics (Nasdaq: FHTX) announced management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The company presentation is scheduled for Wednesday, February 11, 2026 at 3:00 p.m. EST by Adrian Gottschalk, President and CEO.
A live webcast will be available via the company’s Investors "Events & Presentations" page and will remain accessible for 30 days. Management will also conduct one-on-one meetings at the summit.
Foghorn Therapeutics (Nasdaq: FHTX) closed a $50 million registered direct financing on Jan 13, 2026, selling common stock and warrants.
The company sold 2,030,314 common shares at $6.71 per share (a 30% premium to the Jan 9, 2026 Nasdaq price), issued pre-funded warrants for up to 5,421,250 shares at $6.7099, and issued series warrants to buy 3,725,782 shares at $13.42 and another 3,725,782 shares at $20.13. Gross proceeds were approximately $50 million (excluding any proceeds from potential warrant exercises). The financing was sold directly by Foghorn without an underwriter and included participation by BVF Partners, Deerfield Management, Flagship Pioneering and a leading biotech mutual fund.
Foghorn Therapeutics (Nasdaq: FHTX) announced a $50.0 million equity financing led by BVF Partners, Deerfield Management, Flagship Pioneering and a biotech mutual fund, expected to close Jan 13, 2026. The company reported an estimated $208.9 million in cash, cash equivalents, and marketable securities inclusive of the financing, extending runway into the first half of 2028. Clinical and preclinical progress includes an on‑track Phase 1 dose‑escalation trial of FHD‑909 in SMARCA4‑mutant NSCLC, and IND‑tracking selective degrader programs for CBP, EP300, and ARID1B with IND/enabling milestones anticipated in 2026.